Updates in Screening and Surveillance for Barrett’s Esophagus
We have become excellent at treating Barrett’s esophagus (BE) related neoplasia. But to reduce the instance of esophageal adenocarcinoma (EAC) we need to increase the population under surveillance and leverage risk stratification tools to personalize the management of non-dysplastic BE.
Sri Komanduri, MD, FASGE, AGAF Director of Endoscopy
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).